Computational-based drug design of novel small molecules targeting p53-MDMX interaction

References

• Adelusi, T. I., Abdul-Hammed, M., Idris, M. O., Kehinde, O. Q., Boyenle, I. D., Divine, U. C., Adedotun, I. O., Folorunsho, A. A., & Kolawole, O. E. (2021). Exploring the inhibitory potentials of Momordica charantia bioactive compounds against Keap1-Kelch protein using computational approaches. In Silico Pharmacology, 9(1), 39. https://doi.org/10.1007/s40203-021-00100-2
   PubMedGoogle Scholar
• Adelusi, T. I., Oyedele, A.-Q K., Boyenle, I. D., Ogunlana, A. T., Adeyemi, R. O., Ukachi, C. D., Idris, M. O., Olaoba, O. T., Adedotun, I. O., Kolawole, O. E., Xiaoxing, Y., & Abdul-Hammed, M. (2022). Molecular modeling in drug discovery. Informatics in Medicine Unlocked, 29, 100880. https://doi.org/10.1016/j.imu.2022.100880
   Google Scholar
• Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., Matison, M. E., Schneider, S., Huang, X., Yu, D., Andrews, P. S., Reichelt, A., Long, A. M., Yakowec, P., Yang, E. Y., Lee, T. A., & Oliner, J. D. (2009). Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. Journal of Medicinal Chemistry, 52(22), 7044–7053. https://doi.org/10.1021/jm900681h
   PubMed Web of Science ®Google Scholar
• Beckerman, R., & Prives, C. (2010). Transcriptional regulation by p53. Cold Spring Harbor Perspectives in Biology, 2(8), a000935. https://doi.org/10.1101/cshperspect.a000935
   PubMed Web of Science ®Google Scholar
• Bharatham, N., Bharatham, K., Shelat, A. A., & Bashford, D. (2014). Ligand binding mode prediction by docking: Mdm2/mdmx inhibitors as a case study. Journal of Chemical Information and Modeling, 54(2), 648–659. https://doi.org/10.1021/ci4004656
   PubMed Web of Science ®Google Scholar
• Boyenle, I. D., Ogunlana, A. T., Kehinde Oyedele, A. Q., Olokodana, B. K., Owolabi, N., Salahudeen, A., Aderenle, O. T., Oloyede, T. O., & Adelusi, T. I. (2023). Reinstating apoptosis using putative Bcl-xL natural product inhibitors: Molecular docking and ADMETox profiling investigations. Journal of Taibah University Medical Sciences, 18(3), 461–469. https://doi.org/10.1016/j.jtumed.2022.10.014
   PubMed Web of Science ®Google Scholar
• Brooks, C. L., & Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Molecular Cell, 21(3), 307–315. https://doi.org/10.1016/j.molcel.2006.01.020
   PubMed Web of Science ®Google Scholar
• Carter, B. Z., Mak, D. H., Schober, W. D., Koller, E., Pinilla, C., Vassilev, L. T., Reed, J. C., & Andreeff, M. (2010). Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood, 115(2), 306–314. https://doi.org/10.1182/blood-2009-03-212563
   PubMed Web of Science ®Google Scholar
• Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011). Translating p53 into the clinic. Nature Reviews. Clinical Oncology, 8(1), 25–37. https://doi.org/10.1038/nrclinonc.2010.174
   PubMed Web of Science ®Google Scholar
• Cummings, M. D., Schubert, C., Parks, D. J., Calvo, R. R., LaFrance, L. V., Lattanze, J., Milkiewicz, K. L., & Lu, T. (2006). Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chemical Biology & Drug Design, 67(3), 201–205. https://doi.org/10.1111/j.1747-0285.2006.00365.x
   PubMed Web of Science ®Google Scholar
• Dickens, M. P., Fitzgerald, R., & Fischer, P. M. (2010). Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Seminars in Cancer Biology, 20(1), 10–18. https://doi.org/10.1016/j.semcancer.2009.10.003
   PubMed Web of Science ®Google Scholar
• Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., Roller, P. P., & Wang, S. (2006). Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. Journal of Medicinal Chemistry, 49(12), 3432–3435. https://doi.org/10.1021/jm051122a
   PubMed Web of Science ®Google Scholar
• Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342–348. https://doi.org/10.1038/35077213
   PubMed Web of Science ®Google Scholar
• Golestanian, S., Sharifi, A., Popowicz, G. M., Azizian, H., Foroumadi, A., Szwagierczak, A., Holak, T. A., & Amanlou, M. (2016). Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay. Life Sciences, 145, 240–246. https://doi.org/10.1016/j.lfs.2015.12.047
   PubMed Web of Science ®Google Scholar
• Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., Maguire, D., Lattanze, J., Franks, C. F., Zhao, S., Ramachandren, K., Bylebyl, G. R., Zhang, M., Manthey, C. L., Petrella, E. C., … Bone, R. F. (2005). Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. Journal of Medicinal Chemistry, 48(4), 909–912. https://doi.org/10.1021/jm049137g
   PubMed Web of Science ®Google Scholar
• Haupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003). Apoptosis - the p53 network. Journal of Cell Science, 116(Pt 20), 4077–4085. https://doi.org/10.1242/jcs.00739
   PubMed Web of Science ®Google Scholar
• Hsu, K. C., Chen, Y. F., Lin, S. R., & Yang, J. M. (2011). iGEMDOCK: A graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics, 12(Suppl 1), S33. https://doi.org/10.1186/1471-2105-12-S1-S33
   PubMed Web of Science ®Google Scholar
• Khoutoul, M., Lamsayah, M., Al-Blewi, F. F., Rezki, N., Aouad, M. R., Mouslim, M., & Touzani, R. (2016). Liquid–liquid extraction of metal ions, DFT and TD-DFT analysis of some 1, 2, 4-triazole Schiff Bases with high selectivity for Pb (II) and Fe (II). Journal of Molecular Structure, 1113, 99–107. https://doi.org/10.1016/j.molstruc.2016.02.046
   Web of Science ®Google Scholar
• Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., Wang, J., Yu, B., Zhang, J., & Bryant, S. H. (2016). PubChem substance and compound databases. Nucleic Acids Research, 44(D1), D1202–13. https://doi.org/10.1093/nar/gkv951
   PubMed Web of Science ®Google Scholar
• Lee, G. R., Shin, W. H., Park, H. B., Shin, S. M., & Seok, C. O. (2012). Conformational sampling of flexible ligand-binding protein loops. Bulletin of the Korean Chemical Society, 33(3), 770–774. https://doi.org/10.5012/bkcs.2012.33.3.770
   Web of Science ®Google Scholar
• Liu, K., Watanabe, E., & Kokubo, H. (2017). Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. Journal of Computer-Aided Molecular Design, 31(2), 201–211. https://doi.org/10.1007/s10822-016-0005-2
   PubMed Web of Science ®Google Scholar
• Menéndez, C. A., Accordino, S. R., Gerbino, D. C., & Appignanesi, G. A. (2016). Hydrogen bond dynamic propensity studies for protein binding and drug design. PloS One, 11(10), e0165767. https://doi.org/10.1371/journal.pone.0165767
   PubMed Web of Science ®Google Scholar
• Millard, M., Pathania, D., Grande, F., Xu, S., & Neamati, N. (2011). Small-molecule inhibitors of p53-MDM2 interaction: The 2006-2010 update. Current Pharmaceutical Design, 17(6), 536–559. https://doi.org/10.2174/138161211795222649
   PubMed Web of Science ®Google Scholar
• O’Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3, 33. https://doi.org/10.1186/1758-2946-3-33
   PubMed Web of Science ®Google Scholar
• Ogunlana, A. T., Oyedele, A. K., Boyenle, I. D., Ayoola, S. O., Ajibare, A. C., Adeyemi, A. O., Jinadu, L. A., Adenrele, O. T., Alausa, A. O., & Adelusi, T. I. (2022). Computer-aided drug design of some KRAS G12C inhibitors: Targeting the covalent and allosteric binding site for cancer therapy. Informatics in Medicine Unlocked, 32, 101032. https://doi.org/10.1016/j.imu.2022.101032
   Google Scholar
• Oyedele, A. K., Adelusi, T. I., Ogunlana, A. T., Adeyemi, R. O., Atanda, O. E., Babalola, M. O., Ashiru, M. A., Ayoola, I. J., & Boyenle, I. D. (2022). Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction. Journal of Molecular Modeling, 28(6), 142. https://doi.org/10.1007/s00894-022-05131-w
   PubMed Web of Science ®Google Scholar
• Oyedele, A. K., Owolabi, N. A., Odunitan, T. T., Ajibare, A. C., Jimoh, R. O., Abdul Azeez, W. O., Bello-Hassan, M. T., Soares, A. S., Adekola, A. T., Abdulkareem, T. O., Oyelekan, S. O., Ashiru, M. A., Gbadebo, I. O., Olajumoke, H. E., Boyenle, I. D., & Ogunlana, A. T. (2023). The discovery of some promising putative binders of KRAS G12D receptor using computer-aided drug discovery approach. Informatics in Medicine Unlocked, 37, 101170. https://doi.org/10.1016/j.imu.2023.101170
   Google Scholar
• Popowicz, G. M., Czarna, A., Wolf, S., Wang, K., Wang, W., Dömling, A., & Holak, T. A. (2010). Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (Georgetown, Tex.), 9(6), 1104–1111. https://doi.org/10.4161/cc.9.6.10956
   PubMed Web of Science ®Google Scholar
• Ray-Coquard, I., Blay, J. Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., Geho, D., Middleton, S. A., Vassilev, L. T., Nichols, G. L., & Bui, B. N. (2012). Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study. The Lancet. Oncology, 13(11), 1133–1140. https://doi.org/10.1016/S1470-2045(12)70474-6
   PubMed Web of Science ®Google Scholar
• Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001). Regulation and function of the p53 tumor suppressor protein. Current Opinion in Cell Biology, 13(3), 332–337. https://doi.org/10.1016/s0955-0674(00)00216-7
   PubMed Web of Science ®Google Scholar
• Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R. B., Pienta, K. J., Ling, X., Kang, S., Guo, M., … Wang, S. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3933–3938. https://doi.org/10.1073/pnas.0708917105
   PubMed Web of Science ®Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–171. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Vassilev, L. T. (2007). MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine, 13(1), 23–31. https://doi.org/10.1016/j.molmed.2006.11.002
   PubMed Web of Science ®Google Scholar
• Wade, M., Li, Y. C., & Wahl, G. M. (2013). MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Reviews. Cancer, 13(2), 83–96. https://doi.org/10.1038/nrc3430
   PubMed Web of Science ®Google Scholar
• Wang, Y. T., & Cheng, T. L. (2021). Computational modeling of cyclic peptide inhibitor-MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations. Journal of Biomolecular Structure & Dynamics, 39(11), 4005–4014. https://doi.org/10.1080/07391102.2020.1773317
   PubMed Web of Science ®Google Scholar
• Wang, X., & Jiang, X. (2012). Mdm2 and MdmX partner to regulate p53. FEBS Letters, 586(10), 1390–1396. https://doi.org/10.1016/j.febslet.2012.02.049
   PubMed Web of Science ®Google Scholar
• Yamasaki, S., Yagishita, N., Sasaki, T., Nakazawa, M., Kato, Y., Yamadera, T., Bae, E., Toriyama, S., Ikeda, R., Zhang, L., Fujitani, K., Yoo, E., Tsuchimochi, K., Ohta, T., Araya, N., Fujita, H., Aratani, S., Eguchi, K., Komiya, S., … Nakajima, T. (2007). Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin’. The EMBO Journal, 26(1), 113–122. https://doi.org/10.1038/sj.emboj.7601490
   PubMed Web of Science ®Google Scholar
• Yu, S., Qin, D., Shangary, S., Chen, J., Wang, G., Ding, K., McEachern, D., Qiu, S., Nikolovska-Coleska, Z., Miller, R., Kang, S., Yang, D., & Wang, S. (2009). Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. Journal of Medicinal Chemistry, 52(24), 7970–7973. https://doi.org/10.1021/jm901400z
   PubMed Web of Science ®Google Scholar